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Abstract 
Objectives: Economic evaluations of interventions to prevent and control sexually transmitted infections (STIs) 
such as Chlamydia trachomatis are increasingly required to present their outcomes in terms of Quality Adjusted 
Life Years (QALYs) using preference-based measurements of relevant health states. The objectives of this study 
were to critically evaluate how published cost effectiveness studies have conceptualised and valued health states 
associated with chlamydia and to examine the primary evidence available to inform health state utility values 
(HSUVs).  
Methods: A systematic review was conducted, with searches of six electronic databases up to December 2012. 
Data on study characteristics, methods and main results were extracted using a standard template.  
Results: Nineteen economic evaluations of relevant interventions were included. Individual studies considered 
different health states and assigned different values and durations.  Eleven studies cited  the same source for 
HSUVs. Only five primary studies valued relevant health states. The methods and viewpoints adopted varied, 
and different values for health states were generated.  
Conclusions: Limitations in the information available about HSUVs associated with chlamydia and its 
complications have implications for the robustness of economic evaluations in this area. None of the primary 
studies could be used without reservation to inform cost-effectiveness analyses in the UK. Future debate should 
consider appropriate methods for valuing health states for infectious diseases, as recommended approaches may 
not be suitable. Unless we adequately tackle the challenges associated with measuring and valuing HRQL for 
chlamydia and other infectious diseases, evaluating the cost-effectiveness of interventions in this area will 
remain problematic. 
 
 
 
 
  
3 
 
Introduction 
Evidence about the cost-effectiveness of health care interventions is an integral requirement for key decision 
making bodies in many countries, including the UK (1, 2). Many decision making bodies require interventions 
to be assessed in terms of their cost per Quality Adjusted Life Year (QALY), which combines improvements in 
health-related quality of life and life expectancy, together with people’s relative preferences for health states (3). 
Preference- based health state utility values (HSUVs) assign a value to the health states experienced by the 
patient. A value of ‘one’ represents full health and ‘zero’ indicates a health state equivalent to being dead. 
Utility values can be generated directly or indirectly. Standard gamble (SG) or time trade off (TTO) techniques 
generate direct valuations from patients or the public, based on their experiences or hypothetical scenarios. 
Indirect methods typically use an instrument to measure health related quality of life (HRQL) and then apply 
preference values obtained from surveys of the general public (4). The conceptualisation of health states and 
application of HSUVs can have a major influence on the results of cost-effectiveness studies (5, 6). There is a 
growing body of literature with estimates for HSUVs for a wide range of conditions which can be used to 
inform cost-effectiveness studies when reliance on primary data is not possible or valid (7). However, there are 
many disease areas where HSUVs are less widely available, and there are subsets of populations for whom 
preference-based measurements of HRQL are less well researched or where such measurement is perceived as 
more difficult (8, 9).  
Cost-effectiveness studies influence decisions about funding for particular interventions, so their methodological 
quality is extremely important (10). While there has been a growing literature aimed at improving the standard 
of economic evaluations and the decision-analytic models which inform them,  less attention has been devoted 
to the methods involved in identifying and applying HSUVs (6, 11). The conceptualisation and structure of a 
decision-analytic model determines how health states are defined and represented, so disease processes must be 
represented appropriately (12).  
As with all model input parameters estimated from secondary sources, a systematic review of the literature 
should be done to identify, assess and synthesise information to estimate HSUVs and  uncertainty  needs to be 
fully reported and examined (11, 13, 14). Two sets of criteria are relevant to the assessment and selection of 
HSUVs (5). The first relates to the descriptive systems, methods and sources used to generate the values; in the 
UK these are likely to be assessed against recommendations from the National Institute for Health and Care 
Excellence (NICE) (15, 16). The second relates to the relevance of the population in the utility study to that in 
the economic evaluation, in terms of factors such as the condition, its severity, and patients’ age profiles.  
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Many investigators have studied the cost-effectiveness of interventions to prevent, control and treat Chlamydia 
trachomatis (17-19). Chlamydia is the most common bacterial sexually transmitted infection (STI) worldwide 
(20) and in the UK (21), with an estimated prevalence in sexually active 15-25 year olds in the general 
population of 3-6% (22-24). Chlamydia first infects the lower genital tract, causing cervicitis in women and 
urethritis in men, both of which are usually asymptomatic (25) and last more than a year, on average, if 
untreated (26). Infection can clear spontaneously or can ascend to the upper genital tract at any time (27), 
causing symptoms of pelvic inflammatory disease (PID) in 10-15% of women (28, 29) and epididymo-orchitis 
in a smaller proportion of men (25). Symptoms of PID include lower abdominal pain and pain during sexual 
intercourse. Fallopian tube inflammation can, rarely, cause tubo-ovarian abscess. Tubal scarring and blockage 
can cause chronic pelvic pain, ectopic pregnancy and tubal factor infertility (30). There is uncertainty about the 
incidence, duration and timing of late complications because contraception can delay their diagnosis for many 
years and chlamydia is only one cause (31). Chlamydial infection during pregnancy is associated with premature 
labour and neonatal infection can cause conjunctivitis and pneumonia (32, 33).   
Screening for chlamydia infection in asymptomatic sexually active young adults is recommended because of the 
frequency of asymptomatic infections, the severity of complications, and the easy availability of both reliable 
diagnostic tests and  efficacious antibiotic treatment.  If decision makers are to interpret cost-effectiveness 
analyses of interventions to prevent and control chlamydia appropriately, their HSUVs must reflect the impact 
on those experiencing complications.  
The challenges associated with valuing health states for chlamydia 
We believe that there are several challenges to the identification, assessment and utilisation of appropriate 
information on HSUVs for use in economic evaluations of STIs such as chlamydia. First, there are 
considerations relating to the actual state of infection itself. Chlamydia, like many STIs, is often asymptomatic, 
so most infected individuals do not experience any apparent detriment to their quality of life at the time of 
infection (34), even though the average duration of untreated infection is more than one year and people are 
infectious throughout (26). There is qualitative evidence, however, to suggest that being tested for chlamydia 
and receiving a positive diagnosis does have an impact on quality of life, particularly for women (35, 36). 
Second, owing to the obvious ethical and practical issues associated with studying untreated chlamydia, there is 
considerable uncertainty about the natural history of infection and disease, including the timing, incidence and 
duration of complications (37, 38) and rates and risks associated with reinfection (31).  
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Third, chlamydia is only one cause of many of the late sequelae associated with the infection. There is limited 
evidence about whether the aetiology of conditions such as chronic pelvic pain or infertility affects HRQL (39-
41). Qualitative evidence suggests that the stigma associated with STIs mediates the experience of being in the 
health state (35) so HRQL might differ between women with infertility secondary to an STI and those with 
cancer, for example. Fourth, the health states associated with chlamydial disease last for different amounts of 
time; tubal infertility might be permanent, whilst the infection itself and some of its sequelae, such as PID and 
ectopic pregnancy are temporary states (42, 43). Temporary health states might involve different methods for 
valuation, and there is a need to consider how preferences for temporary and permanent states are combined 
(44). Fifth, the sequelae associated with chlamydia sometimes occur many years after the initial infection (37), 
so issues of time preference are likely to impact on the valuation of the health states (45, 46). Finally, the 
burdens associated with the disease are asymmetrical; although both men and women experience infection, the 
main complications associated with chlamydia affect women of reproductive age (31), but fertility problems can 
affect others besides the woman herself. This might affect the conceptualisation of health outcomes and 
decisions about whose preferences should count (47, 48).  
The objectives of this study were to identify and critically evaluate economic evaluations that included QALYs 
as an outcome measure to identify how health states have been conceptualised and valued within cost-
effectiveness studies. Primary studies which valued relevant health states were also located, to examine the data 
which could be used to inform cost-effectiveness studies incorporating HSUVs for chlamydia and its sequelae. 
Methods 
We conducted a systematic review following UK Centre for Review and Dissemination (CRD) guidelines for 
methods and PRISMA guidelines for reporting, where appropriate (49, 50).  
Inclusion criteria 
Papers were included if they met the following criteria: the participants were men or women with, or at risk of, 
sexually transmitted chlamydia or its sequelae; the intervention (for economic evaluations) was any medical 
procedure to prevent, control or treat chlamydia infection or its sequelae; the main outcomes were either cost per 
QALY (for economic evaluations), or the measurement and valuation of health states associated with 
chlamydial infection and its sequelae. We excluded papers which were wholly concerned with conditions 
affecting the pelvic area and not likely to be connected with STIs. 
Search strategy 
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The search strategy was constructed to be as inclusive as possible. Six electronic databases were searched 
(EMBASE, MEDLINE, Web of Science, NHS Economic Evaluation Database (NHS EED), Database of 
Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA)) up to December 2012 
(Appendix 1). The reference lists of potentially relevant papers were then hand searched to identify additional 
studies. We used a three stage process to identify studies for inclusion, using methods which have been 
described in detail elsewhere (51). Two reviewers initially screened papers using the title and abstract to classify 
them into five groups (A to E) (Appendix 2). Second, two reviewers read the full texts of potentially relevant 
studies and further classified them  ( Appendix 2, as above). Quality assessment criteria were not applied to 
exclude studies because so few were identified. For each included study, one reviewer extracted data about the 
study characteristics, the characteristics of the participants, the health states examined, the methods and 
instrument(s) used and the results reported  and a second reviewer checked the data. The data were tabulated and 
the findings of individual studies were compared narratively. 
Results 
The electronic database search identified 6383 published papers, of which 2001 were duplicates. Figure 1 shows 
a flow diagram of the papers identified, retrieved and retained or excluded at each stage, and the categorisation 
of the articles.  
Nineteen economic evaluations using QALYs were identified and all were included for data extraction. There 
were 58 papers which incorporated descriptive measurement of HRQL for chlamydia and associated conditions 
but only five which included preference-based measurement of such health states.  
Economic evaluations using cost per QALY 
Table 1 summarises the characteristics of the 19 studies. Four studies included individuals who were considered 
to be at high risk of STIs (52-55). Ten articles examined interventions to provide chlamydia or gonorrhoea 
screening (52-54, 56-62), while two articles examined different aspects of interventions to treat or prevent PID 
(63, 64). Two studies focused on behavioural interventions (55, 65), and one examined a multifaceted 
intervention to provide information and increased availability of testing and treatment (66). One article was 
concerned with the overall costs and ‘burden of disease’ for chlamydia in a particular country (67) and another 
aimed to estimate the lifetime cost of PID (68). Two studies examined the impact of expedited treatment for 
sexual partners of people with an STI and the impact of contraceptive use on STI prevention (69, 70). Fifteen 
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studies presented their results in terms of natural units, e.g. cost per adverse outcome avoided, as well as cost per 
QALY.  
Authors of five studies applied HSUVs for uncomplicated chlamydia infection, including cervicitis and 
urethritis (52, 54, 60, 61, 66). Most applied HSUVs for one or more named female reproductive tract 
complications: PID (52, 54, 56, 59-67, 69, 70); ectopic pregnancy (54, 56, 57, 59-66, 70); tubal factor infertility 
(54,56,57,59-66, 68) and chronic pelvic pain (54,57,60-66,68). Fewer studies considered male complications 
(54, 56, 59, 65-67) or neonatal complications (56, 59, 66). Just over half of the studies used HSUVs provided by 
a study by the Institute of Medicine in the United States (US) (52, 56-58, 60-64, 66, 68) although some did not 
cite the study directly. Of the remaining evaluations, two studies (59,69) used values elicited from women with 
PID from the work of Smith et al. (71) and one study used the same source but employed values elicited from 
women without PID (67). For one cost-effectiveness study the source of the utility values was unclear (55) and 
the authors of one economic evaluation used a convenience sample to generate their own utility values (70).  
Although the economic evaluations identified largely relied on the same source for HSUVs, there were 
differences in the actual values used, the duration over which they were applied, and around the assumed timing 
and incidence of sequelae (Table 2). The base case values used for chronic pelvic pain varied between 0.6 (57, 
60-64, 66, 68) and 0.79 (67) and were applied for durations from 5 years (54, 60-62, 65) to the rest of the 
woman’s life (67). For ectopic pregnancy, the values adopted varied between 0.58 (60-64, 66) and 1 (57). For 
infertility, the utilities included varied between 0.76 (65) and 0.87 (59). Most analysed the uncertainty 
associated with such values in sensitivity analyses (52, 54-57, 59-70), and some found that this had an impact on 
the results of the cost-effectiveness analysis (63, 65, 68), although factors such as complication and transmission 
rates were more important. The majority of the studies did not provide information about the utility values they 
adopted (other than the source) and very few discussed their appropriateness for the population under study. 
About half of the studies acknowledged the lack of information regarding HSUVs, for example in relation to the 
limitations associated with their study (56, 59-62, 65, 67, 68, 70) (Table 1). 
Primary studies providing HSUVs for relevant health states 
Five primary studies valued HRQL for health states relevant to chlamydia. Their aims and characteristics are 
shown in Table 3; all were based in the US. The studies provided valuations for a range of relevant health states 
including PID, chronic pelvic pain, ectopic pregnancy and tubal factor infertility.  
Pelvic inflammatory disease (PID) 
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Three studies generated utility values for PID (71-73). The values obtained for PID treatment (Table 4) are 
difficult to compare between studies because each study made different assumptions about treatment pathways 
(e.g. inpatient and outpatient care). Two of these measured both public and patient preferences. Smith et al. 
included valuations from women with a history of PID and women with no experience of this condition (71). 
Trent et al. compared the utilities for health states obtained directly from adolescents (assumed to give an 
indication of the views of patients) and their parents (assumed to represent the views of the public) (72). One 
study provided preferences from the perspective of the public using indirect methods. The study conducted by 
the US Institute of Medicine used experts to measure HRQL using the HUI-2 and then used the tariffs 
associated with this instrument for valuation, which are based on surveys of the general population (73). Smith 
et al. used Visual Analogue Scale (VAS) and TTO techniques with a 10 year time horizon to value all health 
states directly and Trent et al. employed VAS and TTO techniques with a 50 year time period (71, 72). The 
health states in the US Institute of Medicine study were not described in full but different time horizons were 
used for different conditions (73).  
Ectopic pregnancy 
Utility values for ectopic pregnancy were generated in three studies (71-73) using the methods and participants 
described above. As for PID, the utility values (Table 4) could not be directly compared between studies due to 
differing assumptions made about treatment pathways. The highest utility value for this condition was generated 
by parents of adolescents for a scenario involving a 15 year old girl experiencing pain and possibly requiring an 
operation with the condition resolved in a few weeks (0.9) (72). The lowest value was generated for inpatient 
treatment for ectopic pregnancy using the HUI-2 (0.23, with an expected duration of 3 days), which was 
followed by outpatient treatment (0.66 for 4 weeks) (73). 
Tubal factor infertility 
Four of the primary studies provided utility vales for tubal factor infertility. Two studies used similar scenarios 
to generate values directly, but with different participants and time horizons. Smith and colleagues reported 
lower utility values for women with experience of PID (0.76) compared with women with no experience of PID 
(0.84), while Trent et al reported similar values for adolescents (0.84) and higher values for their parents (0.91) 
(71, 72). The Institute of Medicine’s study reported a utility value of 0.82 using the HUI-2 tool; infertility was 
assumed to last for the woman’s remaining lifetime (73). Songer et al. used a scaling method to compare 
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preferences for infertility against a range of chronic conditions as they felt that TTO techniques were not 
suitable for eliciting the preferences associated with infertility (75). The authors reported that infertility was 
viewed as worse than a chronic headache by 48% of participants and as worse than paralysis by 12%. There 
were differences in preferences based on experience of previous pregnancies and the number of children 
respondents had. 
Chronic pelvic pain 
Utility values for chronic pelvic pain were reported by four of the studies. Kuppermann et al. obtained 
preference values using Time Trade Off (TTO) techniques with the patients in their cross-sectional study of 
women seeking care for non-cancerous pelvic problems (74). The women generated a utility value of 0.83 for 
their pain, based on living for the rest of their lives with their current symptoms. Smith et al. also provided 
values from a patient perspective; women with experience of PID generated a value of 0.69 for pelvic pain, 
compared with a value of 0.79 provided by women without experience of PID (71). The description of the 
health state used by Smith and colleagues was slightly different to that adopted in the study by Kupperman et al. 
as it was stated that the pain may go away. Trent and colleagues used a similar scenario to that of Smith et al, 
but the subject was a 15 year old girl and 50 year time horizon was used within the TTO exercise. While 
adolescents gave a value of 0.76 for this health state, their parents reported a slightly higher value of 0.85 (72). 
The study by the Institute of Medicine generated a HUI-2 value of 0.60, and the condition was assumed to last 
for the remainder of the woman’s life (73).  
Discussion 
This systematic review found 19 published economic evaluations about chlamydia infection and associated 
sequelae that reported outcomes as cost per QALY. Half of the articles used the same source for HSUVs but 
several applied modified values or altered the duration for which they were applied. Half of the economic 
evaluations mentioned some difficulties associated with valuing the health states for chlamydia. Most studies 
analysed the uncertainty around HSUV estimates for the state of infection and its sequelae through a sensitivity 
analysis but none discussed in detail the implications associated with the primary research informing their 
HSUV estimates. There were five primary studies that provided HSUVs for health states relevant to chlamydia 
infection; all but one used direct methods to value health states.  
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As for many infectious diseases, understanding the impacts of chlamydia upon HRQL involves assessing the 
nature and epidemiology of the sequelae and our ability to link them back to infection. In the majority of the 
economic evaluations limitations around our understanding of HRQL for the health states associated with 
chlamydia and its sequelae were not fully explored and the ways in which health states had been conceptualised 
and valued were not discussed in detail. For example, the primary studies demonstrated that health states were 
valued very differently depending on the characteristics of the research participants (e.g. patients or public), but 
the economic evaluations reviewed did not discuss the implications associated with the values they adopted. In 
economic evaluations of diseases where the primary evidence is limited, balancing the need to adequately reflect 
the decision problem and disease processes against the availability and quality of data can be problematic (12). 
While the economic evaluations have clearly attempted to tackle the complexities involved in understanding the 
impacts of interventions in this area, we believe that it is imperative that such studies fully convey the 
limitations in our knowledge about the sequelae of chlamydia and about preference-based HRQL for these 
conditions, to ensure that decision makers are fully informed and to emphasise the importance of further primary 
research to inform such economic analyses.  
None of utility values reported in the primary studies we identified could be used without reservation to inform 
economic evaluations in the UK. When selecting HSUVs from the literature, it is important to consider both the 
methods used to generate the values and their relevance to the population under consideration (4). In this 
instance, the methods used in the primary studies would need to be considered against the ‘reference case’ 
methods for estimating cost-effectiveness set out by NICE, which recommends that, where possible, HRQL is 
measured directly by patients or their carers and that these measurements are valued by a representative sample 
of the general population using a choice based method (15). The study by the Institute of Medicine relied on 
expert views to measure HRQL, which is generally seen as less preferable than measuring patient experiences of 
health states directly (4). The remaining studies employed scenarios to value HRQL rather than direct patient 
measurement. There might also be some concerns about the generalisability of the studies. The study by 
Kupperman et al. provided values based on the specific symptoms the women with pelvic problems were 
experiencing, and the studies by Smith et al. and Trent et al. were carried out in areas of high STI prevalence in 
the US, which would not apply to the UK general population.  
Infectious diseases and their sequelae offer an intriguing lens through which to analyse methodological debates 
about how we should measure and value the benefits of health care; enabling exploration of key questions such 
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as how should HRQL be described and measured, how should it be valued and whose values should be taken 
into account (5). For chlamydia, it is difficult to measure patient reported HRQL directly because sequelae can 
happen a long time after the initial infection and cannot be aetiologically linked. This means that most primary 
studies to date have employed direct valuation methods using descriptions of health states. However, direct 
valuation methods are seen as less robust, as there is no clear link to patient reported HRQL (4). For conditions 
where it is difficult to measure preferences indirectly, there is a need for further discussion about the most 
effective ways to elicit utility values to inform economic evaluations (76). There is a growing body of research 
examining the impacts of stigma on HRQL in relation to STIs and other conditions (77-80) and there have been 
attempts to include the impacts of stigma in the valuation of health states (81), but further exploration of such 
issues is needed.  
Infectious diseases such as chlamydia involve combinations of short and long-term health states. There is 
evidence that preferences for health states may be partly affected by their duration and there is on-going debate 
about how we overcome such problems (44, 82). There is also discussion about how we incorporate time 
preference within valuations of health states, which is pertinent to research involving chlamydia and other 
diseases, where complications may occur or be detected many years after initial infection (46, 83). The primary 
studies we identified demonstrated that different values were obtained for different groups of participants, which 
has implications for broader methodological discussions about whose preferences should be used to value health 
states (47, 48). This issue is particularly important for STIs because of the asymmetry between men and women 
in the burden associated with the complications of disease, even though both sexes acquire and transmit the 
infection itself. 
We identified two previous systematic reviews focussing on outcomes for economic evaluations relating to 
chlamydia infection. Roberts et al. reviewed economic evaluation and modelling studies in this area published 
up to 2004 (17). Approximately half of the studies reviewed used ‘cost per case detected’ as the main outcome. 
This is not an appropriate base for policy decisions because these are only surrogate endpoints and do not 
determine the success of the intervention for chlamydia. The current review shows that the use of cost per 
QALY has increased markedly, possibly as a reflection of the impact of recommendations made by NICE, the 
Pharmaceutical Benefits Advisory Committee (PBAC) in Australia and other decision-making bodies (15, 16, 
84). A second review described alternative approaches to measure and value the quality of life associated with 
the sequelae of chlamydia and considered studies up to the end of 2011 (85). The authors concluded that it was 
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not possible to reach firm conclusions about the most appropriate techniques for measuring HRQL and valuing 
outcomes for chlamydia. The current review examines how HSUVs have been used within economic 
evaluations, and critically examines the primary data available to inform cost-effectiveness studies, based on a 
wide range of search terms.  
Strengths and limitations 
The main strength of this study is that it provides a comprehensive overview of economic evaluations about 
chlamydia infection that have reported their results in terms of cost per QALY. Another strength is the critical 
appraisal of the HSUVs that have been used in existing economic evaluations alongside a consideration of the 
wider primary evidence on HSUVs and associated methodological issues. There are also weaknesses associated 
with this review. Some studies were not explicit in stating that the condition under study was associated with 
chlamydia. Hence, reviewers had to use their judgement to determine which studies should be included and 
might have incorrectly included or excluded relevant publications. Another weakness relates to the different 
methods that have been used to value HRQL, which makes it difficult to make comparisons between studies and 
reach conclusions on the differences between them. 
Conclusions  
There is limited information about the HSUVs associated with chlamydia infection and its complications, which 
has implications for the robustness of economic evaluations in this area. Future economic evaluations need to be 
firmly rooted in our understanding of the natural history of the disease and its sequelae and fully discuss any 
limitations associated with the underlying evidence, to ensure that decision makers are as informed as possible 
and to inform future research agendas. To be in line with generic NICE guidelines for economic evaluations, 
future research is needed to understand preferences for the health states associated with chlamydia. We would 
argue that such research needs to fully engage with wider methodological debates about how we measure and 
value health states. The valuation of health states for chlamydia and other infectious diseases can be particularly 
challenging because it may not be possible to employ the methods which are generally viewed to be the most 
robust. For example, complications may occur many years after initial infection and cannot be aetiologically 
linked, which means that direct measurement of patient reported HRQL and the application of indirect valuation 
methods is not possible. Thus, there needs to be further exploration of the most appropriate methods of value 
elicitation to use in different settings, to ensure the best match of methods to the aims of the research (76). In 
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addition, further exploration is required around methods for valuing and combining preferences for health states 
of varying duration and occurring over different time horizons. Issues relating to the measurement and valuation 
of the impacts of stigma, and debates about whose preferences count also need to be examined in greater depth. 
Unless we adequately tackle the challenges associated with measuring and valuing HRQL for chlamydia and 
other infectious diseases, evaluating the cost-effectiveness of interventions in this area will remain problematic. 
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Electronic database search (Web of 
Science 1184, MEDLINE 2027, EMBASE 
2969, DARE 80, NHS EED 100, HTA 23): 
6383 citations 
2001 excluded as duplicates 
4080 excluded on basis of title / 
abstract 
Stage I  
Initial categorisation: 301 citations 
78 studies excluded on basis of initial 
categorisation 
Stage II  
Further categorisation: 224 citations 
A(1) = 19, A(2) = 112, A(6) 6 
B(3)=5, B(4) = 58, B(6) = 5 
C(5) = 8, C(6) = 11 
 
1 additional paper 
identified by hand 
searching 
Stage III Quality assessment: 24 studies 
included: A(1), B(3) 
136 studies excluded: A(2), A(6), B(6), 
  
No studies excluded at this stage due to 
low numbers of studies found 
Data extracted for 24 studies: 19 economic 
evaluations, 5 primary studies with health 
state valuations 
58 studies retained for background 
information: B(4) 
Legend: Refer to Appendix 2 for explanation of 
the categorisation criteria 
Figure 1 
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Table 1: Summary of characteristics of included economic evaluations 
Lead Author  Evaluation aims Outcomes Perspective Population 
targeted by 
intervention and 
comparator 
Health states 
included (for 
HSUVs) 
 
Information presented 
about utility values, 
including source, 
participants, methods 
Sensitivity analysis Source 
for 
HSUVs 
QALY MOA 
 
Adams (56) Estimate the cost-effectiveness of 
the National Chlamydia Screening 
Strategy and its alternatives in 
England. 
  Healthcare Men and women Epididymitis, PID, 
EP, TFI, NConj, 
NPneum 
Source cited. Authors 
mention the lack of 
information available on 
utilities 
Probabilistic multivariate 
sensitivity analysis 
(73) 
Aledort (57) Examine the cost-effectiveness of 
gonorrhoea screening in urban 
emergency departments. 
  Societal Women CPP, TFI, EP Source and Tool cited. Duration & weights varied in 
sensitivity analysis 
(73) 
Burgos (55) Evaluate the cost-effectiveness of a 
behavioural intervention among 
female sex workers in Mexico. 
  Healthcare High risk women STI, HIV +/-STIs Authors created their 
own variable to modify 
HRQL according to 
CD4+ counts. 
One, two and multi-way 
sensitivity analyses 
Unclear 
de Vries (58) Estimate the cost- effectiveness of 
repeated screening for Chlamydia 
trachomatis at various time 
intervals compared with one-off 
screening. 
  Societal Men and women  Tool and source cited. Not reported (73) 
Deogan (66)* Assess the cost-effectiveness of a 
community-based intervention to 
provide information, and increase 
the availability of testing, treatment 
and contact tracing. 
  Societal Men and women Infection 
+symptoms, 
epididymitis, PID, 
EP, TFI, CPP, 
NConj, NPneum 
Source and tool cited. Series of sensitivity analyses 
undertaken including 
duration of 10 years for 
sequelae. 
(73) 
Gift (54)* Estimate the cost-effectiveness of 
screening men for chlamydia 
compared with alternative 
strategies. 
  Societal Men and women Infection + 
symptoms, 
epididymitis, PID, 
EP, CPP, TFI 
Source and previous 
study cited. 
One, two and multi-way 
sensitivity analyses. Sequelae 
rate varied in sensitivity 
analysis. 
(60, 73, 
86) 
Gift (69) Evaluate the cost-effectiveness of 
expedited partner therapy compared 
with standard partner referral for 
the treatment of chlamydia or 
gonorrhoea. 
  Healthcare 
and societal 
Men and women PID & sequelae Source cited. Univariate and simultaneous 
sensitivity analyses 
undertaken 
(71, 73) 
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Gillespie (59) Estimate the cost and cost-
effectiveness of opportunistic 
screening for Chlamydia 
trachomatis in Ireland.  
  Healthcare Men and women Epididymitis, PID, 
EP, TFI, NConj, 
NPneum 
Source cited. 
Limitations of data 
included. 
Probabilistic Sensitivity 
Analysis undertaken 
(71, 73) 
Hu (60) Test the cost-effectiveness of 
proposed strategies for chlamydia 
screening. 
  Societal Women Infection, PID, EP, 
TFI, CPP 
Source cited. Authors 
mention the need for 
further information on 
HRQL for PID and 
sequelae. 
Author states that utilities 
were varied widely in 
sensitivity analysis. 
(73) 
Hu (61) Understand the impacts of different 
assumptions about the natural 
history of Chlamydia trachomatis 
on the cost-effectiveness of 
screening strategies. 
  Societal Women Infection, PID, EP, 
TFI, CPP 
Source and tool for 
utilities given. Authors 
mention limited HRQL 
data available on PID 
and sequelae. 
Author states that a one way 
senitivity analysis was 
undertaken on all key 
variables. 
(73) 
Shepherd (65) Examine the effectiveness and cost-
effectiveness of schools-based 
skills building behavioural 
interventions. 
  Healthcare Men and women Epididymitis, PID, 
EP, TFI, CPP 
Sources, participants, 
methods used to 
generate utilities given 
and lack of information 
about HRQL for STIs 
discussed. 
QALY losses per STI case 
and for complications varied 
in sensitivity analysis 
(60, 71)  
Smith (52) Consideration of the effect of time 
from STI acquisition to PID 
development on the cost-
effectiveness of different screening 
intervals. 
  Societal High risk women  Infection, PID, PID 
complications 
Sources given for 
utilities. 
One way and multiway 
sensitivity analyses 
(73) 
Smith (64) Examine the impact of anti-biotic 
costs on cost-effectiveness of PID 
therapy for mild to moderate PID. 
  Societal Women PID, EP, ruptured 
EP, TOA, TFI, CPP 
Source and tool used to 
generate utilities given. 
Utility values varied over a 
broad range in sensitivity 
analyses. 
(73) 
Smith (63) Estimate the cost-effectiveness of 
hospitalisation compared with 
outpatient therapy for mild to 
moderate PID. 
  Societal Women PID, EP, ruptured 
EP, TOA, TFI, CPP 
Source, tool and 
participants cited. 
One way and probabilistic 
sensitivity analyses 
(73) 
Sonnenberg (70) Comparison of the cost-
effectiveness of 13 methods of 
  Societal Women PID, EP Some information about 
methods used to elicit 
Sensitivity analysis, 
including omitting quality of 
Own 
values 
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contraception to no use of 
contraception.  
utilities using a 
convenience sample. 
Methods discussed in 
relation to study 
limitations. 
life adjustment 
Tuite (67) Estimate the burden of disease and 
costs of genital Chlamydia 
trachomatis infection in Canada 
  Societal Men and women Epididymitis, PID, 
PID complications 
Some information 
provided on sources and 
participants. Lack of 
data mentioned. 
Deterministic one way 
sensitivity analysis and 
simultaneous simulation 
(71) 
Walleser (62) Examine the cost-effectiveness of a 
hypothetical opportunistic annual 
screening programme for 
chlamydia, compared with no 
screening. 
  Healthcare Women PID, EP, TFI, CPP Source and tool cited. One and multi-way 
sensitivity analyses. 
(73) 
Wilson (53) Conduct an analysis of the costs of 
testing female sex workers vs. the 
benefits of averting transmission of 
STIs to clients. 
  Healthcare High risk men Infection + 
complications 
Expected value analysis 
undertaken to calculate 
utility loss for STIs 
Not reported Own 
values 
Yeh (68) Estimate a range for the average 
life-time cost of PID and its major 
complications. 
  Societal Women TFI, CPP Details of source given 
and limitations in data 
mentioned. 
Author states that utility 
values varied widely in 
sensitivity analysis, state that 
there is a lack of evidence for 
such values 
(73) 
MOA, major outcome averted; CPP, chronic pelvic pain; EP, ectopic pregnancy; NConj, neonatal conjunctivitis; NPneum, neonatal pneumonia; PID, pelvic 
inflammatory disease; STI, sexually transmitted infection; TOA, tubo-ovarian abscess; TFI, tubal factor, infertility. 
* included different states for PID, EP treatment options.  
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Table 2: Summary of utility values included in economic evaluations, for selected health states 
Lead author Pelvic Inflammatory Disease  
(PID) 
Chronic Pelvic Pain Ectopic Pregnancy Tubal Infertility 
 HSUV Dur. Incid. 
 
HSUV Dur. Incid. 
 
HSUV Dur. Incid. 
 
HSUV Dur. Incid. 
 
Aledort (57)    0.6  10 years 0.18  
 
1  1-2 weeks 0.08  0.82  10 years 0.2  
Deogan (66) OP: 0.63 
IP: 0.57 
IP: 10 days 
OP: 2 days 
0.84a 
0.16 a 
0.6 
 
30 years  
 
0.165a 0.58  4 weeks 0.06 a  0.82  30 years 0.205 a 
Gift (54) OP: 0.66 
IPS:0.79 
IPNS: 0.81 
10 days 
12 days 
12 days 
0.34a 
0.0188a  
0.0412a 
0.64 5 years 0.18a 
 
OP: 0.62 
IP: 0.64  
OP: 28 
days 
IP: 31 days 
OP:0.0510a 
IP: 0.009a 
0.84  10 years 0.05 
Gillsepie (59) 0.992  0.1       0.871 Model run 
for 10 
years 
0.108gh  
Hu (60) 0.65 11 days 0.4a 0.6  5 years 0.18a  
 
0.58 4 weeks 0.09a  0.82 i Until age 
50 
0.2  
(0.10-0.23) 
Hu (61) 0.65 11 days 0.4a 0.6  5 years 0.12c  
 
0.58 4 weeks 0.04c  0.82 i Until age 
50 
0.09  
Shepherd (65) 0.9 11 days 0.037b 0.69  5 years 0.019b 
 
0.79 4 weeks 0.027 b  0.76  15 years 0.067 b  
Smith (52) 0.65   0.028 b          
Smith (64) 0.63  0.032j 0.6   0.073c  0.58   0.01 c  0.82  0.028 c  
Smith (63) OP: 0.63  
IP: 0.57 
 0.032j 0.6   0.073c 0.58   0.01 c  0.82  0.028 c  
Sonnenberg (70) 0.91667   0.01    0.91667  0.005    
Tuite (67) AT: 0.87  
IP: 0.84  
10 days 
2 days 
0.4  
0.08 
0.79 Remaining 
lifetime 
0.18 0.87 4 weeks 0.09  0.84f  Remaining 
lifetime 
0.05  
Walleser (62) 0.65 11 days 0.1b 0.6  5 years 0.03 a 0.58 4 weeks 0.012 a  0.82  Until 
successful 
IVF / 5 
years 
0.01 a  
Yeh (68)    0.6 2 years 0.181    0.82 10 years  0.205 
 
a=applied to PID 
b= applied to positive cases of chlamydia infection 
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c= varied for no. episodes of acute PID 
d= applied to asymptomatic PID 
e=applied to post pid health state 
f= applied to women with infertility workup 
g= applied to symptomatic PID 
h= excludes patients with EP 
i= Infertility QALY only applied to 0.25 who receive an infertility work up 
j = recurrent PID. 
Dur. = Duration 
Incid. = Incidence 
IP = inpatient 
IPS = Inpatient surgical 
IPNS = inpatient non-surgical 
OP = outpatient 
Ranges are not shown. 
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Table 3: Included primary studies with utility values 
Lead author Study Aims Participants Number of 
participants 
Techniques 
used 
Health states valued Direct / 
indirect 
valuation 
Further information on 
methods 
Kuppermann (74) Assess the impact of 
abnormal uterine 
bleeding and pelvic 
pain and pressure on 
HRQL and sexual 
functioning 
Women seeking 
care for non-
cancerous 
pelvic problems 
(aged 31-54) 
By symptoms: 
Pain only = 272  
Pain & bleeding = 278  
Heavy bleeding 
without leiomyomata 
= 190 
Heavy bleeding with 
leiomyomata = 570 
Fibroids with pressure 
= 183 
TTO Pelvic pain, Pain & 
bleeding, Heavy 
bleeding with / 
without leiomyomata, 
Fibroids with 
pressure 
Direct In an interview setting, patients 
asked how many years of their 
remaining lives they would be 
willing to give up to live without 
the symptoms they were 
experiencing. 
Smith (71) Measure quality of 
life utilities for health 
states associated with 
PID 
Women with / 
without a history 
of PID 
(aged 18+) 
By disease history: 
PID: 56 
No PID: 150 
TTO; VAS PID OP, PID IP, 
Ectopic pregnancy, 
Infertility, Chronic 
pelvic pain 
Direct Participants read scenarios to 
describe health states and then 
used a computerised tool to give 
VAS and TTO valuations for 
health states using time trade off 
methods. Subjects were asked to 
trade-off between living 10 years 
in the health state and varying 
amounts of time in full health.  
Songer (75) Identify the value 
that women with PID 
assign to health 
impact of future 
infertility 
Women with 
signs and 
symptoms of 
PID 
By pregnancy history:  
0 live births =   205 
1 live birth = 168 
2 live births = 90 
3 or more = 68 
Other* Infertility Direct Women with PID were asked to 
rate whether life with infertility 
was more or less meaningful 
than life with a series of 7 
chronic conditions. 
Institute of 
Medicine (73) 
Develop a 
quantitative model to 
prioritize the 
development of 
vaccines for 
infectious diseases 
Experts & 
members of 
committee 
Expert committee 
members  
Other Acute urethral 
syndrome, cervicitis / 
bartholinitis, PID OP, 
PID IPNS, IPS, 
OPAIP, Ectopic 
pregnancy (IP/OP), 
Infertility, Chronic 
pelvic pain, Reiters 
syndrome, Arthritis, 
Indirect A Committee to Study Priorities 
for Vaccine Development 
developed scenarios for health 
conditions with input from 
experts. These scenarios were 
used to complete HUI-2 tool, 
which enabled utilities to be 
calculated.  
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Urethritis, 
Epididymitis (OP/IP) 
Trent (72) Investigate and 
compare adolescent 
and parent PID- 
related health utilities 
Adolescents 
(aged 12-19) & 
their ‘parents’ 
(aged 18+) 
By category: 
Adolescents: 134 
Parents: 121 
TTO; VAS PID OP, PID IP, 
Ectopic pregnancy, 
Infertility, Chronic 
pelvic pain 
Direct Adolescent girls and parents 
completed a web based survey 
where they were asked to trade-
off between a longer life with a 
health condition (described in a 
scenario) and a shorter life in 
perfect health. 
PID = Pelvic Inflammatory Disease; SG = Standard Gamble; TTO = Time Trade Off; VAS = Visual Analogue Scale. 
A glossary of the instruments / techniques cited which measure and value health related quality of life is provided in Appendix 3. 
*Songer et al. used a quasi-rating scale preference measure using paired comparisons to obtain the value participants assigned to future fertility. 
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Table 4: Utility values provided by primary studies 
Health state Lead author Result Duration Further information about the health states valued 
Pelvic Inflammatory 
Disease (PID) 
Institute of 
Medicine 
HUI value 
Outpatient only:0.63 
Inpatient – no surgery : 0.57 
Inpatient - surgery: 0.46 
Outpatient after inpatient: 0.83 
Utilities were 
calculated using HUI-2 
PID outpatient treatment was assumed to last for 10 days, and 
inpatient treatment for 2 days.  
 Smith Outpatient treatment 
TTO mean value (SD) 
• Women with PID: 0.90 (0.22) 
• Women without PID: 0.87 (0.26) 
Inpatient treatment 
TTO mean value (SD) 
• Women with PID: 0.82 (0.29) 
Women without PID: 0.84 (0.27) 
10 year time horizon 
for all states 
The outpatient scenario involved a 25 year old woman with pain for 
about 7 days (affecting usual activities) and antibiotic treatment for 
14 days. It is stated that the woman has a very small chance of 
developing complications and a chance of getting PID again in the 
future. The inpatient scenario involved a hospital stay for 2-3 days 
with antibiotics by vein and antibiotic pills for a further 11-12 days at 
home. It is explained that complications are more likely when the 
illness requires hospital treatment.  
 Trent Outpatient treatment 
TTO mean value (SD) 
• Parents: 0.90 (0.27) 
• Adolescents: 0.82 (0.33) 
Inpatient treatment 
TTO mean value (SD) 
• Parents: 0.88 (0.30) 
• Adolescents: 0.78 (0.36) 
50 year time horizon 
for all states 
Scenario involved a 15 year old girl with an adapted version of the 
approach adopted by Smith and colleagues (71). 
Chronic Pelvic Pain Kuppermann 
(74) 
TTO mean value (SD) 
• Pain only: 0.83 (0.01) 
• Pain & bleeding: 0.78 (0.02) 
Full remaining life 72.5% women seeking care for non-cancerous pelvic problems 
experienced pain, 71% experienced bleeding. 
 Smith (71) TTO mean value (SD) 
• Women with PID: 0.69 (0.37) 
• Women without PID: 0.79 (0.29) 
10 year time horizon 
for all states 
Scenario used to value health states involved a 25 year old woman 
with pain that may slowly go away or could stay the same.  
 Institute of 
Medicine (73) 
HUI value 
0.60 
Utilities were 
calculated using HU-I2 
Consequences of PID assumed to have a 5 year lag from infection. 
Chronic pelvic pain assumed to last for remaining life time and affect 
3% infected women. 
 Trent (72) TTO mean value (SD) 
• Parents: 0.85 (0.31) 
• Adolescents: 0.76 (0.38) 
50 year time horizon 
for all states 
Scenario involved a 15 year old girl with an adapted version of the 
approach adopted by Smith and colleagues (71). 
Tubal infertility Smith (71) TTO mean value (SD) 
• Women with PID : 0.76 (0.34) 
• Women without PID: 0.84 (0.29) 
10 year time horizon 
for all states 
Scenario involves a 25 year old woman who has been trying to get 
pregnant for one year but has been unable to do so.  
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 Songer (75) % rating infertility as worse than: 
Sinus congestion 
• All women: 48 
• Women with no children: 76 
Chronic headache 
• All women: 65 
• Women with no children: 62 
Paralysis 
• All women: 12 
• Women with no children: 18 
Scenario suggests that 
infertility would last 
for remaining lifetime 
All the women were had signs and symptoms of PID. They were 
asked to give their own preferences for infertility compared with 
other health states. Infertility defined as ‘you would not be able to 
become pregnant or bear children’.  
 Institute of 
Medicine (73) 
HUI value 
0.82 
Utilities were 
calculated using HUI-2 
Consequences of PID assumed to have a 5 year lag from infection. 
Tubal infertility assumed to last for remaining life time and affect 
3.3% infected women. 
 Trent (72) TTO mean value (SD) 
• Parents: 0.91 (0.25) 
• Adolescents: 0.84 (0.32) 
50 year time horizon 
for all states 
Scenario involved a 25 year old woman with an adapted version of 
the approach adopted by Smith and colleagues (61). 
Ectopic pregnancy Smith (71) TTO mean value (SD) 
• Women with PID:  0.79 (0.34) 
• Women without PID: 0.87 (0.26) 
10 year time horizon 
for all states 
Scenario involved 25 year old woman with an ectopic pregnancy 
requiring a range of treatment options. She was described as 
experiencing pain and possibly needing an operation but it was stated 
that life would return to normal in a few weeks.  
 Institute of 
Medicine (73) 
HUI value 
• 0.58 (outpatient only) 
• 0.23 (inpatient) +  
• 0.66 (outpatient after inpatient) 
Utilities were 
calculated using HUI-2 
All consequences of PID assumed to have a 5 year lag from infection. 
Duration of 4 weeks assumed for outpatient treatment for ectopic 
pregnancy, 3 days for inpatient treatment. 
 Trent (72) TTO mean value (SD) 
• Parents: 0.91 (0.26) 
• Adolescents: 0.82 (0.35) 
50 year time horizon 
for all states 
Scenario involved a 15 year old girl with an adapted version of the 
approach adopted by Smith and colleagues (61). 
 
PID = Pelvic Inflammatory Disease; TTO = Time Trade Off. 
A glossary of the instruments / techniques cited which measure and value health related quality of life is provided in Appendix 3. 
*VAS values are not reported in this table. 
**Songer et al. used a quasi-rating scale preference measure using paired comparisons to obtain the value participants assigned to future fertility. 
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Web only  
Appendix 1: Example of a search strategy - MEDLINE 
# Term 
1 chlamydia.mp. or exp Chlamydia Infections/ or exp Chlamydia/ or exp Chlamydia trachomatis/  
2 gonorrhea.mp. or exp Gonorrhea/ 
3 "pelvic inflammatory disease".mp. or exp Pelvic Inflammatory Disease/ or PID.mp 
4 cervicitis.mp. or exp Uterine Cervicitis/ 
5 ectopic pregnancy.mp. or exp Pregnancy, Ectopic/  
6 epididymitis.mp. or Epididymitis/ 
7 exp Pelvic Pain/ or "chronic pelvic pain".mp. 
8 Infertility, Female/ or tubal infertility.mp.  
9 tubal factor infertility.mp.  
10 "quality of life".mp. or exp "Quality of Life"/  
11 life quality.mp.  
12 hql or qol or HRQL or HRQOL 
13 "health status indicators".mp. or Health Status Indicators/ (18858) 
14  (QALY$ or "Quality adjusted Life Year$").mp. or Quality-Adjusted Life Years/  
15 Health Status/ or health state$.mp. (56390) 
16 (utilit$ or health utilit$).mp.  
17 disutility.mp. 
18 (sf 8 or sf8 or "short form 8" or shortform 8 or sf eight or "short form eight" or "shortform eight").tw.  
19 (sf 12 or sf12 or "short form 12" or shortform 12 or sf twelve or "short form twelve" or "shortform 
twelve").tw.  
20 (sf 36 or sf36 or "short form 36" or shortform 36 or sf thirtysix or "sf thirty six" or "short form thirty six" or 
"short form thirtysix" or "shortform thirty six" or "shortform thirtysix").tw.  
21 (sf 6d or sf6d or "short form 6d" or shortform 6d or sf six or "short form six" or "shortform six").tw.  
22 hui$.mp.  
23 (euro qol or euro qol or eq5d or eq 5d).mp.  
24 standard gamble.mp.  
25 ("time trade off" or tto).mp.  
26 (preference$ or valuation$).mp.  
27 cost utility analysis.mp.  
28 economic evaluation$.mp.  
29 "costs and cost analysis"/  
30 cost benefit analysis.mp. or exp Cost-Benefit Analysis/  
31 "cost effectiveness analysis".mp.  
32 (model$ adj3 economic).mp. or exp models, economic/  
33 markov$.mp.  
34 or/1-10 
35 or/11-34 
36 35 and 36 
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Appendix 2: Categorisation criteria used for economic evaluations and primary studies 
Initial categorisation criteria  Further categorisation criteria 
A A research study which reports on costs and 
outcomes for individuals with/at risk of chlamydia 
and/or associated health states, and includes a 
formal economic evaluation. 
 1 Economic evaluation includes outcomes 
expressed in terms of QALYS (cost-utility 
analysis / cost-effectiveness study) 
B Study contains primary data on measurement 
and/or valuation of HRQL for individuals with/at 
risk of chlamydia and / or associated health states, 
but does not contain an economic evaluation. 
 2 Economic evaluation with outcomes 
expressed in other units e.g. cost per 
complication avoided (e.g. cost-
effectiveness studies) 
C Study includes information relating to the 
measurement and/or valuation of HRQL for 
individuals with/at risk of chlamydia and/ or 
associated health states, but does not report primary 
data 
 3 Primary study of HRQL which 
incorporates preference-based 
measurement (direct and indirect methods 
of utility elicitation) 
D Study may have useful information about 
chlamydia and sequelae but does not obviously fall 
into A-C above (e.g. studies on prevalence or 
treatment options) 
 4 Primary study of HRQL which includes 
non-preference-based measurement only 
(utility values for health states not elicited 
or presented) 
E Study is not a formal economic evaluation and does 
not contain information relating to HRQL for health 
states associated with chlamydia. 
 5 Study reports secondary data on 
preference or non-preference based HRQL 
or is a description of methods only – no 
primary data 
   6 Other, e.g. analysis / discussion of policy, 
costs, prevalence or risk factors 
   7 Study does not contain information 
relevant to the measurement and valuation 
of HRQL for chlamydia and its sequelae 
Studies which were categorised as A-C were read in full and categorised further. Studies which were categorised as 
A1, B3 were retained and data extracted. Studies which were categorised as B4 were retained for background 
information.  
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Appendix 3: Glossary of instruments discussed for measurement and valuation of health related quality of life 
(HRQL) 
Abbreviation Description 
SG Standard Gamble. This technique involves the respondent making a 
choice between an outcome which is certain and a gamble with two 
uncertain outcomes, involving one outcome which is better and one 
which is worse than the certain outcome.  
HUI-2 Health Utilities Index Mark 2. The HUI-2 has seven attributes each with 
3-5 levels. It is a generic instrument designed to measure health status in 
general populations and a range of patient groups. 
TTO Time Trade Off. This technique involves trading off between living a 
longer time living in less than full health, against living a shorter time in 
full health. 
VAS Visual Analogue Scale. A line (usually with defined end points) upon 
which respondents can indicate their judgements about a particular 
concept.  
Source: Reference (66) 
 
 
 
 
